The National Community Pharmacists Association has joined a class action lawsuit against GoodRx, as well as CVS Caremark, Express Scripts, MedImpact Healthcare Systems and Navitus Health Solutions, th

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from $51.00 to $55.00. The adjustment reflects the firm's expectation of an earnings recovery despite ongoing challenges within the Health Care Benefits (HCB) sector.

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while maintaining an Outperform rating. The adjustment comes in anticipation of future performance dynamics,

The lawsuit filed by Attorney General Gentner Drummond will be the first case heard in the newly established Pharmacy Benefit Management Administrative Courts.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical lawsuits against the biggest insulin makers and against the pharmacy middlemen that decide whether to cover the drugmakers’ products.

As PBM services have traditionally been dominated by large companies such as CVS Caremark, Express Scripts and OptumRx, health systems are starting to create alternatives. Here are four more things to know:

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

For many living in America, healthcare is both complicated and expensive. But Mark Cuban thinks there's another way. The billionaire entrepreneur is making waves with a surprisingly simple approach

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.